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Abstract
Dapagliflozin is associated with greater reductions in HbA1c and weight than
saxagliptin in management of type 2 diabetes mellitus (T2DM). The present post hoc
analyses compared the durability of these effects over short- and long-term follow-
up in patients with T2DM who were inadequately controlled with metformin
(≥1500 mg/day) and who were receiving either dapagliflozin (10 mg/day) or
saxagliptin (5 mg/day). Failure of glycaemiccontrol was assessed using the slope of
the change in HbA1c from baseline-over-time regression line (coefficient of failure
[CoF]). CoF was compared directly (dapagliflozin vs saxagliptin) over the short term
(NCT01606007, 24 weeks) and indirectly (placebo-adjusted) over the long term
(NCT00528879 and NCT00121667, 102 weeks). A low CoF value indicated greater
durability. CoF was lower for dapagliflozin versus saxagliptin over 18–24 weeks
(−1.38%/year; 95% CI, −2.41 to −0.35; P = .009) and 20–102 weeks (−0.37%/year;
95% CI, −0.73 to −0.02; P = .04). Fewer dapagliflozin-treated patients versus
saxagliptin-treated patients required rescue medication or discontinued the study
because of failure to achieve glycaemic control at 24 weeks (3.4% vs 9.4%;
P = .0191). In patients with T2DM who were inadequately controlled with metformin,
dapagliflozin was associated with greater durability of glycaemic control than
saxagliptin over 18–24 and 20–102 weeks.
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1 | INTRODUCTION
Although metformin is recommended as a first-line oral antihyper-
glycaemic drug, sodium-glucose cotransporter-2 (SGLT2) inhibitors
and dipeptidyl peptidase-4 (DPP4) inhibitors offer additional
glycaemic control and weight control, with minimal risk of
hypoglycaemia.1,2 Dapagliflozin, an SGLT2 inhibitor, exhibits greater
glycaemic efficacy than saxagliptin, a DPP4 inhibitor, with additional
reductions in weight and systolic blood pressure.3,4 Persistence of the
benefits of dapagliflozin over saxagliptin may affect the choice of
therapy. To date, no head-to-head trials have evaluated the durability
of control of HbA1c, fasting plasma glucose (FPG), SBP, and body
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weight with an SGLT2 inhibitor as compared to a DPP4 inhibitor. We
reviewed data from three phase 3 randomized trials of dapagliflozin
versus saxagliptin in patients with type 2 diabetes mellitus (T2DM)
(NCT01606007, NCT00528879, NCT00121667) and compared the
durability of these effects over short- and long-term follow-up using
coefficient of failure (CoF) methodology.3,5,6
2 | METHODS
2.1 | Short term: direct statistical comparison of
dapagliflozin and saxagliptin
Patients with HbA1c between 8% and 12%, inclusive (64–
108 mmol/mol), who were receiving a stable dose of metformin
(≥1500 mg/day) were randomized to receive either dapagliflozin
(10 mg/day) or saxagliptin (5 mg/day) as add-on therapy.3 Patients
with inadequate glycaemic control from Weeks 6 to 24 were eligible
to receive open-label rescue medication (details of rescue criteria in
Table S1). Patients were included in the CoF analysis if there was at
least one change in HbA1c from baseline (ΔHbA1c) value at Week
18 and a repeat value between Week 18 and Week 24 available for
them in both the dapagliflozin and saxagliptin groups. Patients with
uncontrolled hypertension (SBP ≥160 mm Hg and diastolic blood
pressure ≥100 mm Hg), FPG of at least 270 mg/dL during the 4-week
lead-in period, cardiovascular disease within 3 months of screening,
congestive heart failure (New York Heart Association [NYHA] func-
tional class IV), estimated glomerular filtration rate less than
60 mL/min/1.73 m2 or serum creatinine of at least 1.5 mg/dL in men
and 1.4 mg/dL in women, or significant hepatic disease were
excluded. The endpoints assessed included: (a) number of patients
with HbA1c above 9% (75 mmol/mol) at Week 24 or who received
rescue medication because of failure to achieve pre-specified
glycaemic targets or who discontinued treatment because of lack of
glycaemic control, and (b) time to rescue medication usage or study
discontinuation because of failure to achieve glycaemic targets up to
24 weeks of treatment. Durability of glycaemic control was assessed
as CoF for ΔHbA1c, based on an earlier study.7 CoF was measured
using the slope from a random coefficient model of ΔHbA1c over
Weeks 18–24, excluding data following rescue medication usage.
2.2 | Long term: indirect statistical comparison of
dapagliflozin and saxagliptin
Patients receiving either dapagliflozin (10 mg/day) or saxagliptin
(5 mg/day) or corresponding placebo plus a stable dose of metformin
(≥1500 mg/day) for more than 8 weeks, with HbA1c between 7% and
10%, inclusive (53–86 mmol/mol), C-peptide greater than 1.0 ng/mL,
body mass index of 45 kg/m2 or less for dapagliflozin or 40 kg/m2 or
less for saxagliptin, and serum creatinine of 1.5 mg/dL or less in men
and 1.4 mg/dL or less in women were assessed. Metformin up-
titration was not permitted in either study. Patients with a lack of
glycaemic control from Week 4 to Week 102 were eligible to receive
open-label rescue medication. Rescue criteria were similar in both
studies (Table S1). Data concerning patients who received rescue
medication prior to Week 20 and those who received it after Week
20 were excluded from CoF analysis. Data proximal to initiation of
treatment, prior to Week 20, were also excluded to allow time for
glycation of haemoglobin under treatment. There were at least three
ΔHbA1c observed values at three different visits available for the
patients included in the CoF analysis for the long-term study of
dapagliflozin and saxagliptin (Weeks 20–102). Patients were excluded
if they had symptoms of poorly controlled diabetes or a history of dia-
betic ketoacidosis or hyperosmolar nonketotic coma; if they had used
any other antihyperglycaemic medication 8 weeks prior to the study
or insulin 1 year prior to the study; if they experienced a cardiovascu-
lar event within 6 months of study entry or NYHA stage III/IV conges-
tive heart failure and/or had a known left ventricular ejection fraction
of 40% or less; if they underwent chronic or repeated intermittent
corticosteroid treatment or treatment with potent systemic cyto-
chrome P450 3A4 inhibitors or inducers; if they had active liver dis-
ease and/or clinically significant abnormalities on screening tests of
hepatic, renal, endocrine, metabolic or haematologic function; or if
they had received assessment of an immunocompromised state. The
endpoints assessed were: (a) time to study discontinuation (TTSD)
because of lack of glycaemic control or rescue medication usage
because of failure to achieve the glycaemic target up to 102 weeks,
and (b) durability of glycaemic control between Weeks 20 and 102,
with assessed differences in the placebo-adjusted dapagliflozin and
placebo-adjusted saxagliptin slopes obtained from random coefficient
models of ΔHbA1c over Weeks 20 to 102, excluding data following
rescue medication usage. Exploratory endpoints included changes in
FPG, SBP, and body weight in the 20- to 102-week CoF population.
2.3 | Safety
Safety parameters for all three studies3,5,6 have been reported previ-
ously. Adverse events (AEs), serious AEs, and AEs of special interest,
including hypoglycaemia, genital infections, and urinary tract infec-
tions for studies NCT00528879 and NCT00121667 are summarised
herein.
2.4 | Statistical analyses
Patients in both the short- and long-term analyses were categorized
into two sets: overall (all randomized patients) and CoF (patients
included in the CoF analysis). TTSD because of lack of glycaemic con-
trol or rescue medication usage because of failure to achieve pre-
specified glycaemic targets3,5,6 was assessed using the Kaplan–Meier
method. Indirect statistical comparisons (long-term analysis) were per-
formed using area-under-the-curve estimates for the unweighted dif-
ference in TTSD because of lack of glycaemic control or rescue
medication usage during the periods 20–102 weeks and
96–102 weeks. Direct statistical comparison of the CoF was per-
formed for HbA1c between the dapagliflozin and saxagliptin groups
(short-term analysis). Placebo-adjusted changes from baseline in
HbA1c, FPG, SBP, and body weight were assessed using random-
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coefficient-models analysis with terms for baseline value, treatment,
and treatment by time, with random subject effects of time and inter-
cept (long-term analysis). Indirect statistical comparison of the
placebo-adjusted dapagliflozin versus the placebo-adjusted saxagliptin
groups (Weeks 20–102) was performed for the following variables:
HbA1c, FPG, SBP, and body weight using Review Manager (RevMan)
Version 5.3. (Copenhagen: The Nordic Cochrane Centre, The
Cochrane Collaboration, 2014).8
3 | RESULTS
Demographic and baseline characteristics of dapagliflozin- and
saxagliptin-treated patients were similar in both the short- and long-
term analysis populations (Table S2).
Dapagliflozin-treated patients showed 6.0% (95% CI, 1.0, 11.0;
P < .05) fewer discontinuations because of inadequate glycaemic con-
trol or instances of rescue medication usage because of failure to
achieve glycaemic targets as compared to saxagliptin-treated patients
over 24 weeks. The difference in discontinuations increased to 12.3%
(95% CI, 4.5, 20.0; P < .01) when HbA1c greater than 9%
(75 mmol/mol) at 24 weeks was added to the above criteria.
Dapagliflozin delayed TTSD or rescue medication usage because of
failure to achieve pre-specified glycaemic targets up to Week 24 as
compared to saxagliptin (Figure 1A). Importantly, dapagliflozin-treated
patients experienced a significantly greater improvement in HbA1c
over Weeks 18–24 as compared to saxagliptin-treated patients
(Figure 1B). Mean (standard deviation) CoF was −0.93% (0.37)/year in
dapagliflozin-treated patients as compared to 0.45% (0.38)/year in
saxagliptin-treated patients (Figure 1B). The difference in CoF esti-
mates was −1.38%/year (0.53) (95% CI, −2.41 to −0.35, P = .009).
Dapagliflozin-treated patients had 3% fewer discontinuations or
rescue medication usage as compared to saxagliptin-treated patients
over 20–102 weeks (Figure 1C). When CoF data analysis was
restricted to Weeks 96–102, discontinuation or rescue medication
usage was reported 6% more often (unweighted difference) in
saxagliptin-treated patients as compared to dapagliflozin-treated
patients. Dapagliflozin-treated patients experienced a significantly
greater improvement in HbA1c over Weeks 20–102 as compared to
patients who received placebo. Mean (standard error) CoF was 0.15%
(0.08)/year in dapagliflozin-treated patients as compared to 0.56%
(0.09)/year in patients who received placebo. Mean (standard error)
CoF was 0.46% (0.08)/year in saxagliptin-treated patients as com-
pared to 0.50% (0.10)/year in patients who received placebo. Indirect
statistical comparison revealed a significant negative difference in
F IGURE 1 A, Time to study discontinuation because of lack of glycaemic control or requirement for rescue medication through Week 24; B,
forest plot showing direct comparison of HbA1c CoF for DAPA vs SAXA (Weeks 18–24); C, time to study discontinuation because of lack of
glycaemic control or requirement for rescue medication for DAPA + MET vs SAXA + MET through Week 104; D, forest plot showing placebo-
adjusted indirect comparison of 20-week to 102-week HbA1c CoF for DAPA + MET vs SAXA + MET. CoF, coefficient of failure; DAPA,
dapagliflozin; MET, metformin; PBO, placebo; SAXA, saxagliptin; SD, standard deviation
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HbA1c in placebo-adjusted CoF with dapagliflozin versus saxagliptin
(mean difference [95% CI], −0.37 [−0.73, −0.02]; P = .04) (Figure 1D).
Indirect statistical comparison indicated a relatively greater reduction
in HbA1c with dapagliflozin versus saxagliptin of 0.37%/year, rep-
resenting glycaemic control over Weeks 20–102.
Dapagliflozin-treated patients exhibited significantly greater main-
tenance of FPG, SBP, and body weight over Weeks 20–102 compared
with saxagliptin-treated patients (Figure 2A–C). The positive effects
of dapagliflozin and saxagliptin on SBP were maintained throughout
the study (Figure 2B).
(C)
Group
SAXA + MET
DAPA + MET
Mean SD Total (N) Mean SD
PBO + METDAPA or SAXA + MET
Total (N)
Mean Difference
IV, Fixed (95% CI)
Mean Difference
IV, Fixed (95% CI)
1.12 3.59 134 0.51 4.08 102 0.62 (−0.38, 1.61)
0.47 3.16 113 0.56 3.57 96 −0.09 (−1.01, 0.83)
−1
Favours [DAPA or SAXA + MET] Favours [PBO + MET]
−0.5 0 0.5 1
(B)
Group
SAXA + MET
DAPA + MET
Mean SD Total (N) Mean SD
PBO + METDAPA or SAXA + MET
Total (N)
Mean Difference
IV, Fixed (95% CI)
Mean Difference
IV, Fixed (95% CI)
3.00 12.56 133 3.27 14.97 100 −0.26 (−3.89, 3.36)
1.96 11.37 112 2.58 13.33 96 −0.62 (−4.02, 2.77)
−4
Favours [DAPA or SAXA + MET] Favours [PBO + MET]
−2 0 2 4
(A)
Group
SAXA + MET
DAPA + MET
Mean SD Total (N)
PBO + METDAPA or SAXA + MET
Mean SD Total (N)
Mean Difference
IV, Fixed (95% CI)
Mean Difference
IV, Fixed (95% CI)
13.68 25.47 131 11.87 30.92 101 1.81 (−5.63, 9.25)
3.14 19.57 113 8.86 23.05 95 −5.72 (−11.59, 0.16)
−10
Favours [DAPA or SAXA + MET] Favours [PBO + MET]
−5 0 5 10
F IGURE 2 Forest plots showing placebo-adjusted indirect comparisons of 20-week to 102-week CoF for DAPA + MET vs SAXA + MET with
respect to A, FPG, B, SBP and C, body weight. CoF, coefficient of failure; DAPA, dapagliflozin; FPG, fasting plasma glucose; IV: instrumental
variable; MET, metformin; PBO: placebo; SAXA, saxagliptin; SBP, systolic blood pressure; SD, standard deviation
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Concerning safety, both dapagliflozin and saxagliptin were gener-
ally well tolerated among patients (Table S3). Incidences of
hypoglycaemia were low in both dapagliflozin- and saxagliptin-treated
patients, although the rates of genital and urinary tract infections
were higher in dapagliflozin-treated patients than in saxagliptin-
treated patients.
4 | DISCUSSION
The durability of the beneficial effects of antihyperglycaemic drugs is
important to sustain glycaemic control and counter the chronic pro-
gressive course of T2DM. In the present post hoc analysis, the TTSD
or requirement for rescue medication was delayed by approximately
6 weeks in dapagliflozin-treated patients as compared to saxagliptin-
treated patients over 24 weeks. In addition, dapagliflozin-treated
patients showed a greater ability to sustain glycaemic control than
saxagliptin-treated patients over 24 weeks. Although the 18-week to
24-week HbA1c CoF for dapagliflozin was significantly lower than
that for saxagliptin, longer durability of the glucose-lowering effect of
dapagliflozin as compared to that of saxagliptin was attenuated,
although still corroborated, in a Week 20 to Week 102 interval (indi-
rect comparison–based CoF analysis).
Consistent with the β-cell–independent mechanism of action of
dapagliflozin, lower CoF was observed with dapagliflozin than with
saxagliptin where efficacy may be limited by reduced β-cell capacity,
especially in patients with higher HbA1c.9-11 The greater durability of
HbA1c control with dapagliflozin versus saxagliptin over
20–102 weeks is consistent with a recent meta-analysis that showed
that SGLT2 inhibitors achieved greater efficacy for glycaemic control
than DPP4 inhibitors up to 52 weeks.12 Long-term dapagliflozin treat-
ment in patients with T2DM has achieved glucose-lowering efficacy
and associated reductions in blood pressure and body weight across a
broad spectrum of patients, including those with cardiovascular and
renal comorbidities.13 Thus, our findings support the long-term effi-
cacy and safety profile of dapagliflozin previously reported, as mon-
otherapy or as an adjunct to metformin in patients with inadequately
controlled T2DM.
The similar maintenance of FPG, SBP, and body weight from
Weeks 20–102 in indirect (CoF) comparison of dapagliflozin and
saxagliptin reflects the fact that most of the changes in these parame-
ters occurred in the first 20 weeks from treatment initiation. A recent
post hoc analysis4 of the present short-term trial3 showed that
dapagliflozin significantly reduced the FPG, SBP, and body weight as
compared to saxagliptin over 24 weeks.
Rates of hypoglycaemia with either dapagliflozin or saxagliptin
were low and comparable to the rates observed with placebo; how-
ever, in the long-term analysis, numerically higher rates of both genital
and urinary tract infections were noted in dapagliflozin-treated
patients as compared to saxagliptin-treated patients, which is consis-
tent with dapagliflozin's mechanism of action and safety profile.14
A strength of the CoF method is that it allows for use of all col-
lected data, without need for an arbitrary threshold.15 In addition, the
CoF method used reflects both improvement and deterioration of
glycaemia.15 Regarding limitations, the short-term study may not
allow sufficient time to adequately assess long-term durability of the
efficacy of dapagliflozin as compared to saxagliptin. Moreover, indi-
rect comparisons, while allowing for assessment of long-term relative
efficacy, are associated with the potential for greater interference of
modifying factors such as intercurrent illness and changes in other
medications.16 Additionally, the CoF method relies on “regression
slopes” and does not allow evaluation of conditions of maintained
efficacy unaccompanied by incremental worsening or improvement
over time. Alternative methods must be considered in such instances.
Finally, in this short-term study, baseline HbA1c of patients was
required to be at least 8.0% (64 mmol/mol) and less than 12.0%, inclu-
sive (108 mmol/mol) and, therefore, our analysis may not apply to
patients with baseline HbA1c less than 8.0% (64 mmol/mol).
In conclusion, dapagliflozin offered greater durability of glucose
control than saxagliptin, in both short-term (head-to-head compari-
son) and long-term (indirect comparison) analyses. Consistent with
lower CoF, dapagliflozin-treated patients had fewer discontinuations
or requirements for rescue medication than saxagliptin-treated
patients in both short-term and long-term analyses.
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